ADVERTISEMENT

Pricing Strategies

Romanian Raids On Boehringer Result In Eight-Figure Fine For COPD Market Abuse

Boehringer Ingelheim “made it more difficult” for doctors to prescribe generic versions of its Spiriva (tiotropium) inhalers, Romania’s Competition Council has found, as it levied a fine of more than $25m on the German originator.

M&Ms And PBMs: Sandoz CEO Talks Antibiotics And Ustekinumab

At the J.P. Morgan Healthcare Conference in San Francisco, Sandoz CEO Richard Saynor commented on the “offensively” low pricing for antibiotics in the US – “less than a packet of M&Ms” – while also revealing that the firm has struck a deal with a US PBM for its Samsung Bioepis-partnered Pyzchiva ustekinumab biosimilar to Stelara.

Romanian Raids On Boehringer Result In Eight-Figure Fine For COPD Market Abuse

Boehringer Ingelheim “made it more difficult” for doctors to prescribe generic versions of its Spiriva (tiotropium) inhalers, Romania’s Competition Council has found, as it levied a fine of more than $25m on the German originator.

UK Gabapentin Prices Shoot Up In December

UK prices for gabapentin almost trebled in December, according to the latest figures from WaveData.

Innovation And Accessibility: India’s Advanced Therapy Pricing Challenge

As India prepares to commercialize its first advanced therapies it must engage key stakeholders to ensure successful implementation. Learning from global best practices and managing pricing strategies will be crucial to maximize access, deliver high-quality outcomes, and sustain innovation through reinvestment in R&D.

Sandoz Pays Another $275m Over Price-Fixing

Sandoz announced a $275m settlement to resolve class action antitrust litigation over price-fixing allegations and disclosed that the company made a further provision of $265m linked to the case.

Who Will Emerge Victorious In US Showdown On Stelara?

US biosimilar competition to Stelara is waiting in the wings from the very start of 2025. But with seven ustekinumab rivals already approved by the FDA and set to launch, how will things shake out in such a crowded market? Generics Bulletin looks at the contenders.

Sandoz Forks Out Another $275m Over Price-Fixing

Sandoz has announced a $275m settlement to resolve with end payers class action antitrust litigation in the US over historical price-fixing allegations, as well as disclosing that it has made a further provision of $265m linked to the case.

Denmark Takes A Deep Dive Into Improving Alternative Drug Pricing Agreements

The Danish procurement body for hospital medicines, AMGROS, wants to better understand how to make alternative pricing agreements work and is inviting companies to take part in “deep dive dialogue” to ensure industry proposals hit the mark.

UK Memantine Prices Spike In November

Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.